• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

CNBC: Biogen Eisai Alzheimer's drug Leqembi rejected by European regulator

Quote

anonymous

Guest
Biogen Eisai Alzheimer's drug Leqembi rejected by European regulator

https://www.cnbc.com/amp/2024/07/26...g-leqembi-rejected-by-european-regulator.html

KEY POINTS
  • European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S.
  • The European Commission, the EU's executive body, has a final say. But it almost always follows the drug regulator's recommendations.
  • The regulator said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."
 




















Top Bottom
Back
Quote